nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Nausea—Erlotinib—pancreatic cancer	0.000587	0.000957	CcSEcCtD
Epoprostenol—Decreased appetite—Fluorouracil—pancreatic cancer	0.000586	0.000956	CcSEcCtD
Epoprostenol—Diarrhoea—Sunitinib—pancreatic cancer	0.000585	0.000954	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000582	0.00095	CcSEcCtD
Epoprostenol—Abdominal distension—Epirubicin—pancreatic cancer	0.000581	0.000948	CcSEcCtD
Epoprostenol—Back pain—Docetaxel—pancreatic cancer	0.000577	0.000941	CcSEcCtD
Epoprostenol—Pain—Fluorouracil—pancreatic cancer	0.000577	0.000941	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000576	0.000939	CcSEcCtD
Epoprostenol—Muscle spasms—Docetaxel—pancreatic cancer	0.000573	0.000935	CcSEcCtD
Epoprostenol—Dizziness—Sunitinib—pancreatic cancer	0.000565	0.000922	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000565	0.000921	CcSEcCtD
Epoprostenol—Abdominal pain—Irinotecan—pancreatic cancer	0.000557	0.000908	CcSEcCtD
Epoprostenol—Body temperature increased—Irinotecan—pancreatic cancer	0.000557	0.000908	CcSEcCtD
Epoprostenol—Anaemia—Docetaxel—pancreatic cancer	0.000551	0.000899	CcSEcCtD
Epoprostenol—Pancytopenia—Epirubicin—pancreatic cancer	0.000548	0.000894	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—pancreatic cancer	0.000547	0.000892	CcSEcCtD
Epoprostenol—Vomiting—Sunitinib—pancreatic cancer	0.000544	0.000887	CcSEcCtD
Epoprostenol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000542	0.000885	CcSEcCtD
Epoprostenol—Rash—Sunitinib—pancreatic cancer	0.000539	0.000879	CcSEcCtD
Epoprostenol—Dermatitis—Sunitinib—pancreatic cancer	0.000538	0.000878	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—pancreatic cancer	0.000538	0.000877	CcSEcCtD
Epoprostenol—Urticaria—Fluorouracil—pancreatic cancer	0.000536	0.000874	CcSEcCtD
Epoprostenol—Headache—Sunitinib—pancreatic cancer	0.000536	0.000874	CcSEcCtD
Epoprostenol—Syncope—Docetaxel—pancreatic cancer	0.000535	0.000873	CcSEcCtD
Epoprostenol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000533	0.00087	CcSEcCtD
Epoprostenol—Palpitations—Docetaxel—pancreatic cancer	0.000527	0.00086	CcSEcCtD
Epoprostenol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000524	0.000855	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—pancreatic cancer	0.000522	0.000852	CcSEcCtD
Epoprostenol—Cough—Docetaxel—pancreatic cancer	0.00052	0.000849	CcSEcCtD
Epoprostenol—Hypersensitivity—Irinotecan—pancreatic cancer	0.000519	0.000846	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—pancreatic cancer	0.000518	0.000845	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—pancreatic cancer	0.000515	0.00084	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—pancreatic cancer	0.000515	0.00084	CcSEcCtD
Epoprostenol—Myalgia—Docetaxel—pancreatic cancer	0.000508	0.000828	CcSEcCtD
Epoprostenol—Arthralgia—Docetaxel—pancreatic cancer	0.000508	0.000828	CcSEcCtD
Epoprostenol—Chest pain—Docetaxel—pancreatic cancer	0.000508	0.000828	CcSEcCtD
Epoprostenol—Nausea—Sunitinib—pancreatic cancer	0.000508	0.000828	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—pancreatic cancer	0.000507	0.000828	CcSEcCtD
Epoprostenol—Asthenia—Irinotecan—pancreatic cancer	0.000505	0.000824	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000504	0.000823	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—pancreatic cancer	0.0005	0.000816	CcSEcCtD
Epoprostenol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000497	0.000811	CcSEcCtD
Epoprostenol—Dry mouth—Docetaxel—pancreatic cancer	0.000497	0.00081	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—pancreatic cancer	0.000494	0.000805	CcSEcCtD
Epoprostenol—Asthenia—Gemcitabine—pancreatic cancer	0.000492	0.000803	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—pancreatic cancer	0.000491	0.000801	CcSEcCtD
Epoprostenol—Confusional state—Docetaxel—pancreatic cancer	0.000491	0.000801	CcSEcCtD
Epoprostenol—Oedema—Docetaxel—pancreatic cancer	0.000487	0.000794	CcSEcCtD
Epoprostenol—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000487	0.000794	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—pancreatic cancer	0.000486	0.000792	CcSEcCtD
Epoprostenol—Pruritus—Gemcitabine—pancreatic cancer	0.000485	0.000792	CcSEcCtD
Epoprostenol—Infection—Docetaxel—pancreatic cancer	0.000484	0.000789	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—pancreatic cancer	0.000483	0.000788	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—pancreatic cancer	0.000483	0.000788	CcSEcCtD
Epoprostenol—Diarrhoea—Irinotecan—pancreatic cancer	0.000482	0.000786	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—pancreatic cancer	0.000479	0.000782	CcSEcCtD
Epoprostenol—Shock—Docetaxel—pancreatic cancer	0.000479	0.000781	CcSEcCtD
Epoprostenol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000477	0.000779	CcSEcCtD
Epoprostenol—Pruritus—Fluorouracil—pancreatic cancer	0.000477	0.000778	CcSEcCtD
Epoprostenol—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000477	0.000777	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—pancreatic cancer	0.000476	0.000777	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—pancreatic cancer	0.000476	0.000777	CcSEcCtD
Epoprostenol—Tachycardia—Docetaxel—pancreatic cancer	0.000475	0.000775	CcSEcCtD
Epoprostenol—Skin disorder—Docetaxel—pancreatic cancer	0.000473	0.000771	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—pancreatic cancer	0.00047	0.000767	CcSEcCtD
Epoprostenol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000469	0.000766	CcSEcCtD
Epoprostenol—Dizziness—Irinotecan—pancreatic cancer	0.000466	0.00076	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—pancreatic cancer	0.000464	0.000758	CcSEcCtD
Epoprostenol—Anorexia—Docetaxel—pancreatic cancer	0.000464	0.000757	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—pancreatic cancer	0.000463	0.000756	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000463	0.000755	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—pancreatic cancer	0.000462	0.000754	CcSEcCtD
Epoprostenol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000461	0.000753	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00046	0.00075	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—pancreatic cancer	0.000459	0.000748	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—pancreatic cancer	0.000457	0.000745	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—pancreatic cancer	0.000455	0.000743	CcSEcCtD
Epoprostenol—Hypotension—Docetaxel—pancreatic cancer	0.000455	0.000742	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—pancreatic cancer	0.000454	0.000741	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000454	0.000741	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—pancreatic cancer	0.000449	0.000733	CcSEcCtD
Epoprostenol—Vomiting—Irinotecan—pancreatic cancer	0.000448	0.00073	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—pancreatic cancer	0.000447	0.000729	CcSEcCtD
Epoprostenol—Dizziness—Fluorouracil—pancreatic cancer	0.000446	0.000728	CcSEcCtD
Epoprostenol—Rash—Irinotecan—pancreatic cancer	0.000444	0.000724	CcSEcCtD
Epoprostenol—Dermatitis—Irinotecan—pancreatic cancer	0.000444	0.000724	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000443	0.000723	CcSEcCtD
Epoprostenol—Headache—Irinotecan—pancreatic cancer	0.000441	0.00072	CcSEcCtD
Epoprostenol—Insomnia—Docetaxel—pancreatic cancer	0.00044	0.000718	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—pancreatic cancer	0.000437	0.000713	CcSEcCtD
Epoprostenol—Vomiting—Gemcitabine—pancreatic cancer	0.000436	0.000711	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—pancreatic cancer	0.000435	0.00071	CcSEcCtD
Epoprostenol—Dyspnoea—Docetaxel—pancreatic cancer	0.000434	0.000708	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—pancreatic cancer	0.000433	0.000706	CcSEcCtD
Epoprostenol—Rash—Gemcitabine—pancreatic cancer	0.000432	0.000706	CcSEcCtD
Epoprostenol—Dermatitis—Gemcitabine—pancreatic cancer	0.000432	0.000705	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—pancreatic cancer	0.00043	0.000701	CcSEcCtD
Epoprostenol—Headache—Gemcitabine—pancreatic cancer	0.00043	0.000701	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—pancreatic cancer	0.000429	0.0007	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—pancreatic cancer	0.000429	0.0007	CcSEcCtD
Epoprostenol—Vomiting—Fluorouracil—pancreatic cancer	0.000429	0.000699	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—pancreatic cancer	0.000429	0.000699	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—pancreatic cancer	0.000428	0.000699	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—pancreatic cancer	0.000428	0.000698	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000425	0.000694	CcSEcCtD
Epoprostenol—Rash—Fluorouracil—pancreatic cancer	0.000425	0.000694	CcSEcCtD
Epoprostenol—Dermatitis—Fluorouracil—pancreatic cancer	0.000425	0.000693	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—pancreatic cancer	0.000424	0.000692	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—pancreatic cancer	0.000423	0.00069	CcSEcCtD
Epoprostenol—Headache—Fluorouracil—pancreatic cancer	0.000422	0.000689	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000421	0.000687	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00042	0.000686	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.00042	0.000685	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—pancreatic cancer	0.00042	0.000685	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—pancreatic cancer	0.000419	0.000684	CcSEcCtD
Epoprostenol—Nausea—Irinotecan—pancreatic cancer	0.000418	0.000682	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000416	0.000679	CcSEcCtD
Epoprostenol—Pain—Docetaxel—pancreatic cancer	0.000416	0.000679	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—pancreatic cancer	0.000416	0.000679	CcSEcCtD
Epoprostenol—Chills—Epirubicin—pancreatic cancer	0.000415	0.000676	CcSEcCtD
Epoprostenol—Nausea—Gemcitabine—pancreatic cancer	0.000407	0.000665	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—pancreatic cancer	0.000405	0.00066	CcSEcCtD
Epoprostenol—Nausea—Fluorouracil—pancreatic cancer	0.000401	0.000653	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000398	0.000649	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000397	0.000647	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—pancreatic cancer	0.000397	0.000647	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—pancreatic cancer	0.000396	0.000647	CcSEcCtD
Epoprostenol—Tension—Epirubicin—pancreatic cancer	0.000395	0.000644	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—pancreatic cancer	0.000391	0.000637	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—pancreatic cancer	0.000389	0.000635	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—pancreatic cancer	0.000388	0.000633	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—pancreatic cancer	0.000387	0.000631	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000385	0.000629	CcSEcCtD
Epoprostenol—Abdominal pain—Docetaxel—pancreatic cancer	0.000385	0.000628	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—pancreatic cancer	0.000385	0.000628	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—pancreatic cancer	0.000384	0.000626	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—pancreatic cancer	0.000375	0.000611	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—pancreatic cancer	0.000372	0.000607	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—pancreatic cancer	0.00037	0.000603	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—pancreatic cancer	0.000367	0.000598	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—pancreatic cancer	0.000365	0.000596	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—pancreatic cancer	0.000362	0.00059	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—pancreatic cancer	0.000361	0.000589	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—pancreatic cancer	0.00036	0.000587	CcSEcCtD
Epoprostenol—Hypersensitivity—Docetaxel—pancreatic cancer	0.000359	0.000585	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—pancreatic cancer	0.000358	0.000584	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—pancreatic cancer	0.000355	0.00058	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000354	0.000577	CcSEcCtD
Epoprostenol—Cough—Epirubicin—pancreatic cancer	0.000351	0.000573	CcSEcCtD
Epoprostenol—Asthenia—Docetaxel—pancreatic cancer	0.000349	0.00057	CcSEcCtD
Epoprostenol—Pruritus—Docetaxel—pancreatic cancer	0.000344	0.000562	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—pancreatic cancer	0.000344	0.000561	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—pancreatic cancer	0.000342	0.000559	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—pancreatic cancer	0.000342	0.000559	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—pancreatic cancer	0.000342	0.000559	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—pancreatic cancer	0.000342	0.000558	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—pancreatic cancer	0.000341	0.000557	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00034	0.000555	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—pancreatic cancer	0.000335	0.000546	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—pancreatic cancer	0.000334	0.000545	CcSEcCtD
Epoprostenol—Diarrhoea—Docetaxel—pancreatic cancer	0.000333	0.000543	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—pancreatic cancer	0.000331	0.00054	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—pancreatic cancer	0.000329	0.000537	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000328	0.000536	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—pancreatic cancer	0.000328	0.000536	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000327	0.000534	CcSEcCtD
Epoprostenol—Infection—Epirubicin—pancreatic cancer	0.000326	0.000532	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—pancreatic cancer	0.000325	0.00053	CcSEcCtD
Epoprostenol—Shock—Epirubicin—pancreatic cancer	0.000323	0.000527	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000322	0.000525	CcSEcCtD
Epoprostenol—Dizziness—Docetaxel—pancreatic cancer	0.000322	0.000525	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000321	0.000524	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—pancreatic cancer	0.00032	0.000523	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—pancreatic cancer	0.000319	0.00052	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000317	0.000518	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—pancreatic cancer	0.000317	0.000517	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—pancreatic cancer	0.000317	0.000517	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—pancreatic cancer	0.000317	0.000517	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—pancreatic cancer	0.000316	0.000515	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000315	0.000513	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—pancreatic cancer	0.000313	0.000511	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—pancreatic cancer	0.00031	0.000506	CcSEcCtD
Epoprostenol—Vomiting—Docetaxel—pancreatic cancer	0.000309	0.000505	CcSEcCtD
Epoprostenol—Rash—Docetaxel—pancreatic cancer	0.000307	0.000501	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—pancreatic cancer	0.000307	0.0005	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—pancreatic cancer	0.000307	0.0005	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—pancreatic cancer	0.000306	0.0005	CcSEcCtD
Epoprostenol—Headache—Docetaxel—pancreatic cancer	0.000305	0.000497	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—pancreatic cancer	0.000304	0.000496	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000304	0.000496	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—pancreatic cancer	0.000302	0.000492	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000299	0.000488	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—pancreatic cancer	0.000299	0.000488	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000298	0.000486	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000297	0.000485	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—pancreatic cancer	0.000297	0.000484	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—pancreatic cancer	0.000296	0.000484	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—pancreatic cancer	0.000295	0.000481	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—pancreatic cancer	0.000295	0.000481	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000294	0.000479	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—pancreatic cancer	0.000293	0.000477	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—pancreatic cancer	0.000292	0.000476	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—pancreatic cancer	0.00029	0.000472	CcSEcCtD
Epoprostenol—Nausea—Docetaxel—pancreatic cancer	0.000289	0.000472	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—pancreatic cancer	0.000289	0.000471	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—pancreatic cancer	0.000285	0.000466	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—pancreatic cancer	0.000284	0.000463	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000283	0.000462	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—pancreatic cancer	0.000283	0.000462	CcSEcCtD
Epoprostenol—Pain—Epirubicin—pancreatic cancer	0.000281	0.000458	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—pancreatic cancer	0.000281	0.000458	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000277	0.000451	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—pancreatic cancer	0.000275	0.000448	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000273	0.000445	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000271	0.000442	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—pancreatic cancer	0.00027	0.000441	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000268	0.000438	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000267	0.000436	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—pancreatic cancer	0.000264	0.000431	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000262	0.000428	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—pancreatic cancer	0.000262	0.000427	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—pancreatic cancer	0.000261	0.000425	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—pancreatic cancer	0.00026	0.000424	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—pancreatic cancer	0.00026	0.000424	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—pancreatic cancer	0.00026	0.000423	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—pancreatic cancer	0.00026	0.000423	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000248	0.000405	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000242	0.000395	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—pancreatic cancer	0.000241	0.000394	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—pancreatic cancer	0.00024	0.000392	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—pancreatic cancer	0.00024	0.000392	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—pancreatic cancer	0.000236	0.000384	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—pancreatic cancer	0.000232	0.000379	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—pancreatic cancer	0.000225	0.000366	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000224	0.000365	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—pancreatic cancer	0.000218	0.000356	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—pancreatic cancer	0.000217	0.000354	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—pancreatic cancer	0.000215	0.000351	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—PTCH1—pancreatic cancer	0.000209	0.000539	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTHLH—pancreatic cancer	0.000209	0.000539	CbGpPWpGaD
Epoprostenol—Vomiting—Epirubicin—pancreatic cancer	0.000209	0.000341	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000208	0.000339	CcSEcCtD
Epoprostenol—Rash—Epirubicin—pancreatic cancer	0.000207	0.000338	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—TYMS—pancreatic cancer	0.000207	0.000535	CbGpPWpGaD
Epoprostenol—Dermatitis—Epirubicin—pancreatic cancer	0.000207	0.000337	CcSEcCtD
Epoprostenol—PTGIS—Disease—HIF1A—pancreatic cancer	0.000206	0.000532	CbGpPWpGaD
Epoprostenol—Headache—Epirubicin—pancreatic cancer	0.000206	0.000336	CcSEcCtD
Epoprostenol—PTGIS—Disease—TSC2—pancreatic cancer	0.000205	0.000531	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SHH—pancreatic cancer	0.000203	0.000524	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SHH—pancreatic cancer	0.000203	0.000524	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000201	0.00052	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000201	0.00052	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APOE—pancreatic cancer	0.000201	0.000519	CbGpPWpGaD
Epoprostenol—Dizziness—Doxorubicin—pancreatic cancer	0.000201	0.000328	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—IAPP—pancreatic cancer	0.0002	0.000517	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IAPP—pancreatic cancer	0.0002	0.000517	CbGpPWpGaD
Epoprostenol—Nausea—Epirubicin—pancreatic cancer	0.000195	0.000318	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—pancreatic cancer	0.000193	0.000315	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—PTCH1—pancreatic cancer	0.000192	0.000496	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTHLH—pancreatic cancer	0.000192	0.000496	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTCH1—pancreatic cancer	0.000192	0.000496	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTHLH—pancreatic cancer	0.000192	0.000496	CbGpPWpGaD
Epoprostenol—Rash—Doxorubicin—pancreatic cancer	0.000192	0.000312	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—pancreatic cancer	0.000191	0.000312	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—SST—pancreatic cancer	0.000191	0.000493	CbGpPWpGaD
Epoprostenol—Headache—Doxorubicin—pancreatic cancer	0.00019	0.00031	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000188	0.000487	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JAG1—pancreatic cancer	0.000187	0.000483	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH3—pancreatic cancer	0.000186	0.000481	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOTCH1—pancreatic cancer	0.000185	0.000479	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SRC—pancreatic cancer	0.000183	0.000473	CbGpPWpGaD
Epoprostenol—Nausea—Doxorubicin—pancreatic cancer	0.00018	0.000294	CcSEcCtD
Epoprostenol—PTGIS—Disease—EGF—pancreatic cancer	0.000179	0.000463	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—pancreatic cancer	0.000178	0.000461	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CNR1—pancreatic cancer	0.000176	0.000455	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NRAS—pancreatic cancer	0.000176	0.000455	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SST—pancreatic cancer	0.000176	0.000454	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SST—pancreatic cancer	0.000176	0.000454	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000173	0.000448	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000173	0.000448	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JAG1—pancreatic cancer	0.000172	0.000444	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JAG1—pancreatic cancer	0.000172	0.000444	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH3—pancreatic cancer	0.000171	0.000443	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH3—pancreatic cancer	0.000171	0.000443	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000171	0.000442	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GCG—pancreatic cancer	0.00017	0.00044	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SRC—pancreatic cancer	0.000168	0.000435	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOE—pancreatic cancer	0.000168	0.000435	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000166	0.000428	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—pancreatic cancer	0.000164	0.000424	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—pancreatic cancer	0.000164	0.000423	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AGTR1—pancreatic cancer	0.000162	0.00042	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CNR1—pancreatic cancer	0.000162	0.000419	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CNR1—pancreatic cancer	0.000162	0.000419	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NRAS—pancreatic cancer	0.000162	0.000419	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STK11—pancreatic cancer	0.00016	0.000413	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CD—pancreatic cancer	0.000159	0.000412	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	0.000159	0.000412	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000157	0.000407	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000157	0.000407	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GCG—pancreatic cancer	0.000157	0.000405	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GCG—pancreatic cancer	0.000157	0.000405	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000152	0.000394	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000152	0.000394	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CG—pancreatic cancer	0.000152	0.000393	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—pancreatic cancer	0.000152	0.000391	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—pancreatic cancer	0.000151	0.000389	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CD—pancreatic cancer	0.00015	0.000388	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AGTR1—pancreatic cancer	0.000149	0.000386	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AGTR1—pancreatic cancer	0.000149	0.000386	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STK11—pancreatic cancer	0.000147	0.000381	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STK11—pancreatic cancer	0.000147	0.000381	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—pancreatic cancer	0.000147	0.000379	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000144	0.000373	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SMAD4—pancreatic cancer	0.00014	0.000362	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—pancreatic cancer	0.000139	0.00036	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—pancreatic cancer	0.000139	0.00036	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CB—pancreatic cancer	0.000139	0.000359	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000139	0.000358	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000138	0.000358	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000138	0.000358	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—pancreatic cancer	0.000138	0.000356	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HES1—pancreatic cancer	0.000137	0.000354	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—pancreatic cancer	0.000135	0.000348	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CD—pancreatic cancer	0.000134	0.000345	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000133	0.000343	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000133	0.000343	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000131	0.000339	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMAD4—pancreatic cancer	0.000129	0.000333	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMAD4—pancreatic cancer	0.000129	0.000333	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—pancreatic cancer	0.000129	0.000333	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—pancreatic cancer	0.000128	0.000331	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000128	0.00033	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000128	0.00033	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HES1—pancreatic cancer	0.000126	0.000325	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HES1—pancreatic cancer	0.000126	0.000325	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—pancreatic cancer	0.000126	0.000325	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—pancreatic cancer	0.000124	0.00032	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—pancreatic cancer	0.000123	0.000318	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000121	0.000312	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000121	0.000312	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—pancreatic cancer	0.00012	0.00031	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—pancreatic cancer	0.00012	0.00031	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—pancreatic cancer	0.000119	0.000306	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CB—pancreatic cancer	0.000116	0.000301	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—pancreatic cancer	0.000116	0.000299	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000116	0.000299	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—pancreatic cancer	0.000115	0.000298	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—pancreatic cancer	0.000115	0.000296	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TSC2—pancreatic cancer	0.000114	0.000296	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—pancreatic cancer	0.000114	0.000294	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—pancreatic cancer	0.000112	0.000289	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SRC—pancreatic cancer	0.000111	0.000288	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—pancreatic cancer	0.00011	0.000285	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—pancreatic cancer	0.00011	0.000285	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—pancreatic cancer	0.00011	0.000283	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—pancreatic cancer	0.000107	0.000278	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—pancreatic cancer	0.000107	0.000277	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—pancreatic cancer	0.000106	0.000273	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—pancreatic cancer	0.000106	0.000273	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TSC2—pancreatic cancer	0.000105	0.000272	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TSC2—pancreatic cancer	0.000105	0.000272	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—pancreatic cancer	0.000105	0.00027	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKBIA—pancreatic cancer	0.000104	0.00027	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH1—pancreatic cancer	0.000103	0.000267	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—pancreatic cancer	0.000103	0.000266	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—pancreatic cancer	0.000103	0.000266	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—pancreatic cancer	0.000101	0.000261	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—pancreatic cancer	0.000101	0.000261	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—pancreatic cancer	0.000101	0.000261	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—pancreatic cancer	0.000101	0.000261	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—pancreatic cancer	0.000101	0.00026	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGF—pancreatic cancer	9.99e-05	0.000258	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—pancreatic cancer	9.98e-05	0.000258	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—pancreatic cancer	9.96e-05	0.000257	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PRSS1—pancreatic cancer	9.77e-05	0.000252	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—pancreatic cancer	9.76e-05	0.000252	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKBIA—pancreatic cancer	9.6e-05	0.000248	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKBIA—pancreatic cancer	9.6e-05	0.000248	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH1—pancreatic cancer	9.51e-05	0.000246	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH1—pancreatic cancer	9.51e-05	0.000246	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—pancreatic cancer	9.3e-05	0.00024	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—pancreatic cancer	9.3e-05	0.00024	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—pancreatic cancer	9.3e-05	0.00024	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—pancreatic cancer	9.3e-05	0.00024	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—pancreatic cancer	9.22e-05	0.000238	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—pancreatic cancer	9.2e-05	0.000238	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGF—pancreatic cancer	9.19e-05	0.000237	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGF—pancreatic cancer	9.19e-05	0.000237	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—pancreatic cancer	8.88e-05	0.000229	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.8e-05	0.000227	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—pancreatic cancer	8.7e-05	0.000225	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—pancreatic cancer	8.47e-05	0.000219	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—pancreatic cancer	8.47e-05	0.000219	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—pancreatic cancer	8.47e-05	0.000219	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ARG2—pancreatic cancer	8.47e-05	0.000219	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—pancreatic cancer	8.17e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—pancreatic cancer	8.17e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.1e-05	0.000209	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.1e-05	0.000209	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—pancreatic cancer	8e-05	0.000207	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—pancreatic cancer	8e-05	0.000207	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—pancreatic cancer	7.99e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—pancreatic cancer	7.84e-05	0.000203	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—pancreatic cancer	7.74e-05	0.0002	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—pancreatic cancer	7.44e-05	0.000192	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMP—pancreatic cancer	7.4e-05	0.000191	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—pancreatic cancer	7.39e-05	0.000191	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.35e-05	0.00019	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—pancreatic cancer	7.35e-05	0.00019	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—pancreatic cancer	7.19e-05	0.000186	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—pancreatic cancer	7.12e-05	0.000184	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—pancreatic cancer	7.12e-05	0.000184	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—pancreatic cancer	7.12e-05	0.000184	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—pancreatic cancer	7.1e-05	0.000183	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—pancreatic cancer	6.93e-05	0.000179	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—pancreatic cancer	6.92e-05	0.000179	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—pancreatic cancer	6.86e-05	0.000177	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—pancreatic cancer	6.85e-05	0.000177	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—pancreatic cancer	6.85e-05	0.000177	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—pancreatic cancer	6.8e-05	0.000176	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—pancreatic cancer	6.8e-05	0.000176	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—pancreatic cancer	6.73e-05	0.000174	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—pancreatic cancer	6.69e-05	0.000173	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—pancreatic cancer	6.61e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—pancreatic cancer	6.61e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—pancreatic cancer	6.55e-05	0.000169	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—pancreatic cancer	6.55e-05	0.000169	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—pancreatic cancer	6.53e-05	0.000169	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—pancreatic cancer	6.38e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—pancreatic cancer	6.38e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—pancreatic cancer	6.32e-05	0.000163	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—pancreatic cancer	6.32e-05	0.000163	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—pancreatic cancer	6.2e-05	0.00016	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—pancreatic cancer	6.19e-05	0.00016	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—pancreatic cancer	6.19e-05	0.00016	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—pancreatic cancer	6.16e-05	0.000159	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—pancreatic cancer	6.16e-05	0.000159	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.11e-05	0.000158	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—pancreatic cancer	6.04e-05	0.000156	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—pancreatic cancer	6.01e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—pancreatic cancer	6.01e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—pancreatic cancer	5.98e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—pancreatic cancer	5.97e-05	0.000154	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GLP1R—pancreatic cancer	5.97e-05	0.000154	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DPYD—pancreatic cancer	5.87e-05	0.000152	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—pancreatic cancer	5.8e-05	0.00015	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—pancreatic cancer	5.71e-05	0.000148	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—pancreatic cancer	5.71e-05	0.000148	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	5.57e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—pancreatic cancer	5.56e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—pancreatic cancer	5.56e-05	0.000144	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—pancreatic cancer	5.56e-05	0.000144	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—pancreatic cancer	5.55e-05	0.000143	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.51e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—pancreatic cancer	5.51e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—pancreatic cancer	5.51e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—pancreatic cancer	5.49e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—pancreatic cancer	5.49e-05	0.000142	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—pancreatic cancer	5.44e-05	0.00014	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.32e-05	0.000137	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—pancreatic cancer	5.14e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—pancreatic cancer	5.12e-05	0.000132	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—pancreatic cancer	5.12e-05	0.000132	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—pancreatic cancer	5.1e-05	0.000132	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—pancreatic cancer	5.1e-05	0.000132	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—pancreatic cancer	5e-05	0.000129	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—pancreatic cancer	5e-05	0.000129	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.85e-05	0.000125	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—pancreatic cancer	4.73e-05	0.000122	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—pancreatic cancer	4.73e-05	0.000122	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—pancreatic cancer	4.72e-05	0.000122	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—pancreatic cancer	4.57e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—pancreatic cancer	4.37e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—pancreatic cancer	4.34e-05	0.000112	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—pancreatic cancer	4.34e-05	0.000112	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CD44—pancreatic cancer	4.31e-05	0.000111	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.22e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—pancreatic cancer	4.2e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—pancreatic cancer	4.2e-05	0.000109	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.18e-05	0.000108	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCG—pancreatic cancer	4.14e-05	0.000107	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—pancreatic cancer	4.02e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—pancreatic cancer	4.02e-05	0.000104	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STK11—pancreatic cancer	3.89e-05	0.0001	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—pancreatic cancer	3.86e-05	9.96e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.65e-05	9.43e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—pancreatic cancer	3.55e-05	9.17e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—pancreatic cancer	3.55e-05	9.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—pancreatic cancer	3.34e-05	8.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—pancreatic cancer	2.72e-05	7.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.57e-05	6.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	2.45e-05	6.34e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—pancreatic cancer	2.37e-05	6.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	2.16e-05	5.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.88e-05	4.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.86e-05	4.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.63e-05	4.2e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.15e-05	2.96e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—pancreatic cancer	9.37e-06	2.42e-05	CbGpPWpGaD
